Dako Augments Diagnostic/Drug Tandem Strategy Post-Merger
This article was originally published in The Gray Sheet
Executive Summary
DakoCytomation will develop an epidermal growth factor (EGF) receptor diagnostic kit to work in tandem with a cancer drug that blocks EGF receptors
You may also be interested in...
Abbott/Vysis PathVysion HER-2 Test Labeling Cleared To Carry Herceptin
Vysis will file an amendment to its PathVysion PMA to include retrospective outcome data from Genentech comparing the fluorescence in situ hybridization (FISH) test with immunohistochemistry (IHC) in its product labeling
Dako HercepTest To Launch Oct. 27 In Conjunction With Genentech Herceptin
Market release of the Dako HercepTest will commence Oct. 27, the company said, following FDA premarket approval of the immunohistochemical anti-HER2 assay on Sept. 25.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.